SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?


To: A.J. Mullen who wrote (1457)3/30/2009 12:06:31 PM
From: tuck  Respond to of 2274
 
See this post by Dew.

siliconinvestor.com

I gather Arena prespecified the responder analysis. They win on regulatory grounds on efficacy, so valvulopathy remains the regulatory concern. How unimpressive is the weight loss? Doesn't it compare pretty well to it's valvulopathic predecessor? As such, couldn't it be a commercial success in combos?

Cheers, Tuck